WHO clears China’s CanSino COVID vaccine for emergency use – WHIO TV 7 and WHIO Radio

GENEVA – (AP) – The World Health Organization said Thursday it had granted emergency use authorization for the coronavirus vaccine made by China’s CanSino Biologics, the 11th such vaccine to receive the green light.

The United Nations health agency said the single-dose CanSino vaccine was found to be around 92% effective against severe COVID-19 and 64% effective in preventing people from developing symptoms of the disease. The WHO Vaccine Expert Panel has recommended the vaccine for anyone aged 18 and over.

The CanSino vaccine uses a harmless virus called an adenovirus to deliver the coronavirus spike protein into the body, which then triggers an immune response. The technology is similar to vaccines made by Johnson & Johnson and AstraZeneca, which use different adenoviruses.

Last year, China’s top infectious disease official acknowledged that the country’s local vaccines offered weak protection against COVID-19 and may need to be mixed with booster doses of new RNA vaccines. messenger.

Amid the emergence of COVID-19 variants like delta, omicron, and its subvariants, messenger RNA vaccines have proven to be more effective than more traditional vaccines.

CanSino’s WHO clearance means the UN-backed COVAX effort to distribute vaccines to poor countries can now buy and deliver vaccines made by the Chinese company. Last year, COVAX signed an agreement to buy more than half a billion Chinese vaccines made by Sinopharm and Sinovac.

It is not known how many of these doses are used. Many countries that rely on COVAX for their vaccine programs have expressed a preference for mRNA vaccines made by Moderna and Pfizer.


Follow AP’s coverage of the pandemic at https://apnews.com/hub/coronavirus-pandemic

Back To Top